ClinicalTrials.gg
Active, not recruitingNCT04433234Updated Oct 6, 2026

Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy

A Phase 2 interventional study of DS-5141b in Duchenne Muscular Dystrophy, sponsored by Daiichi Sankyo Co., Ltd.. Active, not recruiting at 2 sites in Japan. Open to male participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Daiichi Sankyo Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 6, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
5 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies in Muscular Dystrophy, Duchenne with a site in Japan — 2 open to participants now, 9 under way, 4 of them phase 3. Muscular Dystrophy, Duchenne · Japan.

Planned enrollment
23rd of 26
8 · median 62
Started
2020
with 2 others
Phase 2
8 of 27
1 open now
Registered
18th of 27
by date
Lead sponsor
2 of 27
Daiichi Sankyo Co., Ltd.

Among the 27 studies in Muscular Dystrophy, Duchenne with a site in Japan, this one is the 23rd largest by planned enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2020, is one of 8 in phase 2, and was the 18th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

2 of the 27 studies in Muscular Dystrophy, Duchenne with a site in Japan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 5 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Dystrophy, Duchenne with a site in Japan, or all of them as a file.
02

Study summary

This is a multicenter, open-label, long-term, extension, phase 2 study to evaluate the safety and efficacy of long-term treatment with DS-5141b in patients with DMD who have completed DS5141-A-J101.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne muscular dystrophy
  • DMD
  • Oligonucleotides, antisense
  • Exon skipping
  • DS-5141b
04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has competed a study of DS5141-A-J101

Exclusion criteria

Exclusion Criteria:

  • Significant safety issues in a study of DS5141-A-J101
  • Patient who does not consent to use appropriate
  • Patient not appropriate to participant in the study as determined by the Investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    DS-5141b 2.0 mg/kg

    Participants who will receive DS-5141b 2.0 mg/kg once weekly.

    Drug: DS-5141b

  • Experimental
    DS-5141b 6.0 mg/kg

    Participants who will receive DS-5141b 6.0 mg/kg once weekly.

    Drug: DS-5141b

Interventions

  • DrugDS-5141b

    Administered via subcutaneous injection once weekly

    Also known as: Renadirsen

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: From first injection to after the last injection of DS-5141b in this study (within approximately 2 years)

  2. Change in distance walked during 6-minute walk test (6MWT)

    Time frame: Every 3 months (within approximately 2 years)

  3. Change in time to stand (TTSTAND)

    Time frame: Every 3 months (within approximately 2 years)

  4. Change in time in Timed up and go test

    Time frame: Every 3 months (within approximately 2 years)

  5. Change in time in 10-meter Run/Walk test

    Time frame: Every 3 months (within approximately 2 years)

  6. Change in score in the North Star Ambulatory Assessment (NSAA)

    Time frame: Every 3 months (within approximately 2 years)

  7. Change in score in the Performance of Upper Limb (PUL)

    Time frame: Every 3 months (within approximately 2 years)

  8. Change in Left Ventricular Ejection Fraction percentage (LVEF %)

    Time frame: Every 6 months (within approximately 2 years)

  9. Change in in Forced Vital Capacity (FVC) (percent predicted)

    Time frame: Every 6 months (within approximately 2 years)

  10. Change in Muscle Strength Measured by Quantitative Muscle Strength Assessment

    Time frame: Every 3 months (within approximately 2 years)

Secondary outcomes

  1. Concentration of DS-5141a in plasma

    Time frame: Every 3 months (within approximately 2 years)

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Jan 2027, 79 months after the start.

Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 79 months is above that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.

Completion moved once since we started tracking on Sep 25, 2026: Jan 2027 → Jan 2031, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2020
First posted
Jun 16, 2020
StartActual
Jun 30, 2020
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2031was Jan 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Jan 31, 2027→Jan 31, 2031
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Study completion Jan 31, 2027→Jan 31, 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04433234
Responsible party
Sponsor
First posted
Jun 16, 2020
Start date
Jun 30, 2020
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2031 (estimated)
Last update
Oct 6, 2026

Study contacts

Clinical Study Leader
study director · Daiichi Sankyo Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion